Pegcetacoplan: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
C3 complement inhibition impairs opsonization of encapsulated bacteria. Serious and potentially fatal infections by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B may occur. This is a boxed warning for the subcutaneous formulation.
A signal for increased conversion from dry AMD to neovascular (wet) AMD was observed in phase 3 trials. The mechanism is not fully understood. Patients must be monitored for signs of nAMD and treated promptly.
Intravitreal injection carries risks of endophthalmitis, retinal detachments, and other ocular adverse events. These are general risks of the intravitreal injection procedure.
Discontinuing pegcetacoplan or inadequate transition from C5 inhibitors may result in breakthrough hemolysis in PNH patients. A 4-week overlap with eculizumab is required during transition.
⚠️Important Warnings
- •Boxed warning (Empaveli): Serious infections caused by encapsulated bacteria. Vaccination required at least 2 weeks before treatment. Life- threatening and fatal infections may occur even in vaccinated patients.
- •nAMD conversion (Syfovre): Patients should be monitored for signs of neovascular AMD conversion. Prompt anti-VEGF treatment if conversion occurs.
- •Breakthrough hemolysis (Empaveli): Do not abruptly discontinue pegcetacoplan or stop eculizumab overlap prematurely. Monitor for hemolysis during treatment transitions.
- •Endophthalmitis (Syfovre): Intravitreal injections carry a risk of endophthalmitis. Use proper aseptic technique. Instruct patients to report any signs of infection promptly.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Approved | Empaveli FDA-approved May 14, 2021 for PNH in adults. Syfovre FDA-approved February 17, 2023 for GA secondary to AMD. Both marketed by Apellis Pharmaceuticals. |
| European Union | Approved (PNH only) | Aspaveli (pegcetacoplan for PNH) approved by EMA December 2021. Syfovre (pegcetacoplan for GA) received a negative CHMP opinion and was not approved by the EMA for the GA indication. |
| International | Approved (select markets) | Approved for PNH in US, EU, and additional markets. The GA indication (Syfovre) is approved only in the US. Regulatory status varies by country and indication. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 75+ community reports
View community protocolsCritical Safety Information#
Pegcetacoplan has two distinct safety profiles depending on the formulation and indication. Empaveli (subcutaneous, PNH) carries a boxed warning for serious infections, while Syfovre (intravitreal, GA) has ocular-specific risks including a signal for neovascular AMD conversion.
Empaveli (PNH) Risks#
Serious Infections (Boxed Warning)#
The most significant risk of systemic pegcetacoplan is serious infection caused by encapsulated bacteria:
- C3 role in immune defense: C3b opsonization is critical for clearing encapsulated organisms. C3 inhibition impairs this defense more broadly than C5 inhibition
- Organisms of concern: Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type B
- Vaccination: Required for all three organisms at least 2 weeks before starting treatment
- Residual risk: Vaccination reduces but does not eliminate infection risk
- Monitoring: Patients must be educated on signs of serious infection and instructed to seek emergency care immediately
Breakthrough Hemolysis#
- Discontinuing pegcetacoplan may lead to complement reactivation and acute hemolysis
- The 4-week overlap with eculizumab during transition is critical
- Patients should be monitored for at least 8 weeks after discontinuation for signs of hemolysis
- Signs include elevated LDH, reticulocytosis, hemoglobinuria, and decreasing hemoglobin
Syfovre (GA) Risks#
Neovascular AMD Conversion#
A safety signal for increased conversion to neovascular (wet) AMD was observed in the OAKS and DERBY trials:
- Mechanism not fully understood; may relate to complement modulation of angiogenic balance in the retina
- Patients should be monitored for signs of nAMD at each visit (fluid on OCT, hemorrhage, acute vision loss)
- If conversion occurs, prompt anti-VEGF treatment should be initiated
- This signal contributed to the EMA's negative opinion for the GA indication
Ocular Complications#
General risks of intravitreal injection apply:
- Endophthalmitis: Rare but potentially vision-threatening; aseptic technique essential
- Retinal detachment: Rare; monitor for symptoms
- Vitreous hemorrhage: Uncommon
- Elevated intraocular pressure: Transient; monitor post-injection
Regulatory and Legal Status#
Pegcetacoplan has a complex regulatory landscape reflecting the dual-indication profile:
| Jurisdiction | PNH (SC) | GA (IVT) | Notes |
|---|---|---|---|
| United States (FDA) | Empaveli (May 2021) | Syfovre (Feb 2023) | Both approved |
| European Union (EMA) | Aspaveli (Dec 2021) | Not approved | CHMP negative opinion for GA |
| International | Varies | US only | PNH approval in multiple markets |
EMA Rejection of Syfovre#
The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of intravitreal pegcetacoplan did not outweigh the risks for geographic atrophy. Key concerns included:
- Modest effect sizes on GA lesion growth (19-22% reduction)
- No improvement in visual function endpoints
- Signal for increased nAMD conversion
- Discordant results between OAKS and DERBY at 12 months
Risk Mitigation#
For Empaveli (PNH) Prescribers#
- Verify vaccination status against encapsulated bacteria
- Ensure 4-week eculizumab overlap during transition
- Educate patients on signs of serious infection and breakthrough hemolysis
- Monitor hemolysis parameters during treatment and for 8 weeks after discontinuation
- Consider antibiotic prophylaxis for high-risk patients
For Syfovre (GA) Ophthalmologists#
- Use aseptic intravitreal injection technique
- Monitor for nAMD conversion at each visit with OCT
- Initiate anti-VEGF promptly if conversion occurs
- Discuss benefit-risk balance with patients, particularly given the lack of visual function improvement
- Consider monthly vs every-other-month dosing based on individual risk-benefit assessment
Medical Disclaimer#
The information provided here is for educational purposes only and does not constitute medical advice. Pegcetacoplan (Empaveli and Syfovre) are prescription medications that should only be used under the supervision of qualified healthcare providers. All treatment decisions should be made in consultation with physicians experienced in managing PNH or retinal diseases.
Related Reading#
Frequently Asked Questions About Pegcetacoplan
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.